article thumbnail

Dr. Amanda Antons Joins Arnold & Porter’s Intellectual Property & Technology Practice in Chicago

Arnold Porter

Arnold & Porter announced today that Dr. Amanda Antons has joined the firm’s Intellectual Property & Technology practice as counsel, resident in Chicago. She has significant research experience and knowledge in the biotechnology and the life sciences industries including work on T cell/HIV interactions.

article thumbnail

GAO Publishes Science & Tech Spotlight on Biorecycling of Plastics

Brag

Biological recycling, or biorecycling, is an emerging technology that uses microbes, such as bacteria or fungi, to break down plastic into its basic components for reuse. According to GAO, entities seeking to engage in biorecycling could face a “complicated legal landscape” that may pose a challenge for the emerging technology.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Earth System Interventions for Sustainability

Legal Planet

Importantly (and often misunderstood), he meant not that we are gods, but instead that technologies have given humanity powers that had previously been exclusive to the gods. I thus wrote the paper “ Earth System Interventions as Technologies of the Anthropocene ,” which was published (open access!)

article thumbnail

Arnold & Porter's Environmental Litigation Practice Named 2022 'Law Firm of the Year' by Best Lawyers

Arnold Porter

News - Best Lawyers has named Arnold & Porter as a "Law Firm of the Year" in the "Litigation - Environmental" category. The firm also received 43 national rankings and 102 metropolitan rankings (Chicago, DC, Denver, Houston, Los Angeles, New York, and San Francisco) in the "Best Law Firms" report. Biotechnology Law.

Law 75
article thumbnail

Developments in US Antitrust Litigation—2020 Year in Review

Arnold Porter

The direct purchasers' suit, filed in 2012, alleged that GSK and Teva violated the antitrust laws through their settlement agreement to end a patent dispute over GSK's anti-epilepsy drug Lamictal and Teva's generic equivalent, lamotrigine.[[N:Complaint, and its subsidiary, AbbVie Biotechnology, Ltd. 3d 184 (3d Cir. Abbvie Inc.

2020 98
article thumbnail

From Commodification to Conservation: Restoring Agrobiodiversity through Seed Breeding – Part I: 

National Sustainable Agriculture Coalition (NSAC)

The Corporate Consolidation of Seed Breeding Over the past decades, we have seen a hyper consolidation of the seed market with over 50% of seed sales coming from companies that are owned by four large biotechnology corporations. Source: Philip H. To strictly analyze the cost of seed, consider that corn farmers who paid $26.65

article thumbnail

Policy News: September 12, 2022

ESA

The Government Accountability Office issued five new priority recommendations to the White House Office of Science and Technology Policy. Revesz is a former dean and current professor at New York University’s School of Law and the founder of the Institute for Policy Integrity, an environmental think tank. Read the full report here.

2022 75